Best-in-Class Label for Blood Cancer Trial by Billion Euro Biotech

07/12/2015 - 3 minutes

Latest results of MorphoSys candidate for Multiple Myeloma show that it was Celgene’s loss when it abandoned the phase I/IIa trial partnership on blood cancer.

morphosysAnnounced at the American Society of Hematology (ASH) Annual Meeting this weekend in Orlando (US), the phase I/IIa drug for blood cancer from MorphoSys has shown good tolerability for this Munich based Biotech. Indeed, the results are so encouraging that the candidate has best-in-class tolerability profile for the 52 patients with relapsed/refractory Multiple myeloma enrolled on the trial.

MOR202 is a fully human monoclonal HuCAL antibody targeting CD38, a highly expressed and validated target in multiple myeloma. CD38 is a promising target for the treatment of this type of cancer and potentially for hematological malignancies too. As Arndt Schottelius from MorphoSys explained:

The clinical study will continue as planned, focusing on combination cohorts, as we see the highest potential for MOR202 in combination therapy

An effective antibody against this target could not only change future treatment regimens in multiple myeloma,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!